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Abstract: Pre-clinical data and human trials indicate that resveratrol supplementation may help
to counteract diabetes. Several mechanisms of action have been proposed to explain its metabolic
benefits, including activation of sirtuins and estrogen receptors (ER) to promote glucose transporter
type-4 (GLUT4) translocation and increase glucose uptake. Resveratrol can also enhance vasodilator
function, yet the possibility that this action might help to alleviate insulin resistance in type-2 diabetes
mellitus has received little attention. In this brief review we propose that, by restoring impaired
endothelium-dependent vasodilatation in insulin resistant individuals resveratrol increases blood
perfusion of skeletal muscle, thereby facilitating glucose delivery and utilization with resultant
improvement of insulin sensitivity. Thus, circulatory improvements by vasoactive nutrients such as
resveratrol may play a role in preventing or alleviating insulin resistance.
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1. Does Resveratrol Improve Insulin Sensitivity? Evidence from Clinical Trials
The search for naturally occurring compounds that may help to prevent type 2 diabetes mellitus
(T2DM) is gaining increasing attention. Whilst insulin resistance is a risk factor for developing T2DM,
there are no specific pharmaceutical interventions to counteract insulin resistance, and only general
diet and physical activity recommendations, for which adherence is poor and individual outcomes vary
greatly. Trans-resveratrol, a stilbene found in edible plants such as berries, cocoa, peanut skins and red
grapes, and therefore in red wine, is one promising candidate bioactive that has been recently identified
with the potential to counteract (i.e., prevent as well as treat) insulin resistance. It has been shown to
have many important physiological actions, primarily attributable to the activation of NAD-dependent
histone deacetylases (sirtuins). However, with a similar molecular structure to estradiol (E2) and
binding affinity for estrogen receptors (ER), it can also be considered as a phytoestrogen [1,2]. Interest in
this compound was stimulated by a link between red wine consumption and lower cardiovascular
disease mortality in the French population (the French Paradox), with resveratrol identified as a
potential primary mediator. As a result, potential cardiovascular benefits of resveratrol have been
extensively studied [3,4].
Insulin resistance, the primary abnormality of and risk factor for T2DM, is characterized by
reduced insulin-mediated glucose uptake in skeletal muscle, liver and adipose tissue in people with
normal glucose tolerance. In healthy individuals, a postprandial rise in glucose triggers pancreatic
secretion of insulin which activates glucose transporter type-4 (GLUT4) transporters (highly expressed
in muscles) to facilitate glucose uptake into muscle cells, liver and adipocytes for energy storage,
whilst inhibiting the rate of glycogen breakdown in the liver [5,6]. Moreover, insulin can influence the
rate of glucose uptake in skeletal muscle and adipose tissue by acting on the endothelium to recruit
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unperfused capillaries and increase blood flow [7]. Within one to three hours, the blood glucose level
starts to decline and β-cells reduce insulin secretion. Because skeletal muscles are major sites for glucose
uptake and storage, the vasodilator effects of insulin in skeletal muscle is of primary importance in
this review. Insulin resistance, initiated by ageing, excessive dietary fat or glucose intake, or adiposity,
can concertedly disrupt endothelial function, which can lead to impaired endothelium-dependent
vasodilatation, reduced tissue perfusion and, therefore, decreased glucose disposal, triggering a
self-perpetuating cycle of hyperinsulinaemia and hyperglycaemia [8,9]. The Homeostatic Model
for Assessment of Insulin Resistance (HOMA-IR) is a validated algorithm that uses the product of
fasting blood glucose and insulin to assess the extent to which the glucose-insulin feedback loop is
disrupted [10].
Interest in and evidence for the potential of resveratrol to counteract T2DM by improving insulin
sensitivity has grown. In a meta-analysis of 11 intervention trials conducted in T2DM [11], two showed
that resveratrol could benefit T2DM by reducing fasting glucose, insulin, HOMA-IR and/or glycated
haemoglobin (HbA1c). Movahed et al. found a 50% reduction in HOMA-IR and 14% improvement
in HbA1c in T2DM adults following supplementation of 1000 mg/day for 45 days [12], with similar
findings by Bhatt et al. [13]. Likewise, in the absence of a glucose-lowering effect, insulin levels
were reduced by 5% in T2DM patients with periodontal disease following 4 weeks of 480 mg/day
resveratrol [14]. However, a recent meta-analysis by Zhu et al. of nine studies performed in T2DM
was only able to confirm a beneficial effect of resveratrol for reducing HOMA-IR [15], while other
clinical studies examining the influence of resveratrol on diabetes biomarkers (i.e., insulin sensitivity
and glucose tolerance) have been inconclusive, making the interpretation of results difficult [16,17].
It was argued that there may be an optimal dose range for metabolic effects since Brasyno et al. and
Goh et al. did not find changes in insulin concentrations in T2DM patients receiving resveratrol doses
of 10 mg/day and 3000 mg/day respectively [18,19]. A recent study by Timmers et al. [20] randomised
obese volunteers with well-controlled T2DM to placebo or resveratrol (150 mg/day) for 30 days
to evaluate insulin sensitivity via hyperinsulinaemic-euglycaemic clamps. However, hepatic and
peripheral insulin sensitivity were unaffected by resveratrol, despite an ex vivo increase in muscle
mitochondrial function and reduction of systolic blood pressure. The latter finding supports the
robust benefits of resveratrol for cardiovascular function [3]. Nonetheless, it was argued that the trial
participants were using a relatively high dose of metformin, which resulted in higher plasma levels of
dihydro-resveratrol, a metabolite of resveratrol, suggesting a greater breakdown of resveratrol that
may have affected its bioavailability. In addition, there is no evidence for insulin lowering in T2DM
patients with advanced complications such as foot ulcers [21]. However, this study was not powered
to detect changes in diabetic biomarkers. The potential for resveratrol to counteract severe T2DM is
yet to be confirmed.
While Liu et al. concluded no significant antidiabetic benefits of resveratrol for non-T2DM adults
in their meta-analysis [11], some clinical studies have shown otherwise. Witte et al. [22] found that
resveratrol supplementation for six months reduced HbA1c in overweight but otherwise healthy older
adults. In the same population, Timmers et al. observed a modest 14% insulin-lowering effect with
150 mg/day of resveratrol for 30 days. The improvement in insulin sensitivity was attributed to the
enhancement of mitochondrial function in skeletal muscle and reduction in triglyceride and leptin
levels, thereby enhancing substrate utilisation efficiency [23]. In contrast, a four-week trial using the
same dose (150 mg/day) failed to show changes in lipids, inflammatory markers or glucose metabolism
in overweight and slightly obese older men and women [24]. Similarly, six weeks of 2–3 g/day of
resveratrol failed to change glucose tolerance or insulin sensitivity in older glucose-intolerant adults
without T2DM [16]. Arguably the high resveratrol dose may have adversely affected insulin action via
excessive activation of peroxisome proliferator-activated receptor-γ coactivator-1α (PGC1α), a central
regulator of mitochondrial biogenesis and metabolism [25]. However, this finding contradicts a
study in metabolic syndrome patients that found significant reductions in the area-under-the-curve
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of the postprandial rise in insulin concentration following 90 days of resveratrol treatment at
1500 mg/day [26].
The purpose of this review is to outline possible mechanisms by which resveratrol could improve
insulin sensitivity, including the effects of human sirtuin 1 (SIRT1) activation on substrate utilisation.
Given the conflicting clinical data on its metabolic effects and the emerging evidence that resveratrol
can improve circulatory function [16,27], we hypothesise an additional mechanism by which resveratrol
may help to counteract T2DM, viz. enhancing microvascular perfusion of skeletal muscle to facilitate
glucose uptake and utilization.
2. Mechanisms by Which Resveratrol May Improve Insulin Sensitivity in Skeletal Muscle
2.1. Human Sirtuin 1 (SIRT1) and AMP-Activated Protein Kinase (AMPK) Activation
Since its discovery, resveratrol has been shown to exert multifaceted effects on mitochondrial
function, bone metabolism, cancer and neurodegenerative disease [28,29], the most consistent being its
activation of sirtuins, which may also increase lifespan [30]. The activation of SIRT1 by resveratrol,
resulting in increased in AMP-activated protein kinase (AMPK) activity, is thought to be a panacea for
preventing age-induced diseases, including diabetes [25,31]. AMPK is expressed in various tissues,
e.g., brain, liver, skeletal muscle and adipocytes [32]. Skeletal muscle is a major site for glucose uptake
and glycogen synthesis (~80%) [33]. The postprandial elevation of blood glucose triggers insulin
release, which suppresses endogenous glucose production (breakdown of glycogen) in muscle cells
and activates GLUT4 transporters (highly expressed in muscles) to facilitate uptake of glucose into
muscle cells for glycogen synthesis, thereby reducing blood glucose concentration [5,6]. As a master
regulator of metabolism, the activation of AMPK upregulates mitochondrial biogenesis, inhibiting
triglyceride synthesis and stimulating glucose uptake and fatty acid oxidation in the skeletal cells,
which in turn improves insulin sensitivity [32,34].
Resveratrol has been shown to stimulate AMPK activity in hepatocytes [35], skeletal muscle
cells [36], and neurons [37]. In insulin-resistant mice treated with resveratrol for 12 weeks,
improvements in insulin-sensitivity and glucose tolerance were accompanied by upregulation of SIRT1
protein in liver and soleus muscle and consequent AMPK activation [38]. The anti-hyperglycaemic
effect of chronic resveratrol treatment has been shown to improve whole-body and tissue specific
insulin-stimulated glucose uptake in insulin-resistant rats on a high cholesterol-fructose diet by
stimulating GLUT4 translocation to the cell membrane and insulin receptor phosphorylation in soleus
muscles [2]. In diabetic men, resveratrol supplementation (3000 mg/day for 12 weeks) upregulated
GLUT4 expression in skeletal muscle by enhancing SIRT1 expression and AMPK phosphorylation.
However, these improvements did not translate into reductions of HbA1c or HOMA-IR [19]. It is
still unclear whether SIRT1–AMPK activation by resveratrol is linked to improved insulin sensitivity
in humans.
2.2. Increased Glucose Uptake via Activation of Estrogen Receptors (ER)
ER, particularly ER-α, have recently been recognized to play a prominent role in modulating
glucose disposal, primarily through effects on several proteins of the insulin-signaling pathway and
on expression and translocation of GLUT4 [39]. GLUT4 expression in skeletal muscle cell membranes
also depends on activation of ER-α to stimulate phosphorylation of protein kinase-B (Akt) and AMPK,
for translocation of GLUT4 [40]. With a higher affinity for ER-α than ER-β, resveratrol has been
shown to bind to ER on endothelial cells to concomitantly improve vasodilatation and stimulate
skeletal muscle glucose uptake [41–43]. Inhibition of ER markedly suppressed resveratrol-induced
muscle glucose uptake [2]. In human umbilical vein endothelial cells that express both ER-α and ER-β,
a single dose of resveratrol can activate endothelial nitric oxide synthase (eNOS) to rapidly stimulate
vasodilatation [44]. Furthermore, under euglycaemic-hyperinsulinaemic conditions, resveratrol
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treatment can induce ER-phosphorylation but not ER protein expression, supporting the view that the
metabolic actions of resveratrol are mediated via ER activation [2].
Compared with resveratrol or insulin treatment alone, combined administration of resveratrol
and insulin synergistically increased skeletal muscle glucose uptake and GLUT4 translocation in
streptozotocin-induced diabetic rats [32]. However, this benefit was not seen with resveratrol and
ER-agonist (E2) treatment, suggesting that resveratrol and E2 act on the same signaling pathway to
enhance muscle glucose uptake. It can be noted that there was a dose-dependent reduction in plasma
glucose levels in the rats; however, when the maximally effective resveratrol dose (0.5 mg/kg) was
reached, no further benefit was observed with increasing doses. This observation has important
implications for dosing in human studies.
2.3. Improving Glucose Utilisation by Increasing Blood Flow in Skeletal Muscle
There is a mutual interaction between metabolic dysregulation and endothelial dysfunction in
the development of insulin resistance. Indeed, the endothelium can also become insulin-resistant
such that insulin-mediated vasodilatation is impaired [45]. Yet the role of microvascular dysfunction
as a possible antecedent of insulin resistance that also synergistically contributes to cardiovascular
morbidity and end-organ damage in T2DM has received little attention [46], even though Julius et al.
had hypothesized a hemodynamic link between insulin resistance and hypertension 30 years ago [47].
The IMPORTANCE of a healthy circulation cannot be understated, particularly the responsiveness of
the endothelium to enable arterioles to rapidly dilate or constrict in response to demands; this is vital
for survival and the optimal functioning of tissues. The loss of endothelium-dependent vasodilatation
caused by ageing, adiposity, excessive dietary fat and glucose intake or any other pathological influence
marks the initial stage of vascular dysfunction. It is primarily mediated by the incapacity of vascular
endothelial cells to synthesize and release the endogenous vasodilator, nitric oxide, giving rise to
increased vascular resistance and causing impaired tissue perfusion. Consequently, this can lead
to the suboptimal delivery of glucose and insulin to skeletal muscle, leading to a self-perpetuating
cycle of hyperinsulinaemia and hyperglycaemia that ultimately results in glucose intolerance and
exacerbates the endothelial dysfunction [9,48,49]. This impairment leads to arterial hypertension,
capillary rarefaction (reduction in the density of capillaries) and tissue ischaemia, resulting in end-organ
damage as in diabetic retinopathy.
The mechanisms through which resveratrol may improve insulin sensitivity in T2DM are
complex, encompassing reduced adiposity and changes in gene expression and activity of key
enzymes [19,23]. Additionally, resveratrol may act to restore endothelium-dependent vasodilator
function, thereby counteracting the vasoconstriction caused by hyperinsulinaemia. In insulin-resistant
adults, excessive insulin levels promote vasoconstriction and vascular remodeling to create an
ischaemic environment for tissues [8]. It is well established that resveratrol improves eNOS function
by enhancing its expression and activity, resulting in increased nitric oxide bioavailability for
vasodilatation, and prevents eNOS from uncoupling to reduced oxidative stress [50]. Furthermore,
the simultaneous activation of SIRT1-AMPK and ER pathways by resveratrol can also indirectly
increase eNOS expression and activity [50]. Hence, it is plausible that resveratrol-induced improvement
in vasodilator capacity may restore perfusion to further promote glucose uptake in skeletal muscles,
thereby reducing insulin demand (Figure 1).
We were the first to demonstrate a dose-dependent increase in flow-mediated dilatation of the
brachial artery during functional hyperaemia (FMD) following resveratrol consumption in mildly
hypertensive and overweight adults [51]. FMD is a common method of assessing vasodilatory capacity
in the systemic circulation and is closely associated with risk factors for cardiovascular disease [52].
Reduced FMD is an early marker of vascular pathology in obese individuals which precedes the loss of
systemic arterial compliance and is linked to poor oxidative capacity in skeletal muscle [53]. Similarly,
FMD is halved in T2DM compared to non-T2DM [54]. Chronic resveratrol supplementation (75 mg/day
for 6 weeks) reversed the impairment of systemic vasodilator function in overweight/obese adults [27].
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Interestingly, the magnitude of improvement in FMD was inversely proportional to their baseline
vasodilator capacity, suggesting that mild endothelial dysfunction is reversible with resveratrol and that
future intervention studies should select their subjects appropriately. A recent study [53] has confirmed
the acute vasodilator benefit of a single 300 mg dose of resveratrol in treated hypertensive adults,
aged 45–65 years, with poor FMD. They observed a greater increase of FMD following resveratrol
consumption in adults with elevated low density lipoprotein cholesterol, emphasizing the potential
for resveratrol to counteract endothelial dysfunction. Interestingly, they also found a significant
70% improvement of FMD in women but not in men, who had an 11% improvement of FMD [55].
This finding is consistent with the preclinical evidence that resveratrol, as a phytoestrogen, can also
exert vasodilator effects through ER [2].
Figure 1. Multiple mechanisms by which resveratrol may counteract insulin resistance: activation of
AMP-activated protein kinase–human sirtuin 1 (AMPK–SIRT1) pathways to enhance mitochondrial
biogenesis and fatty acid oxidation; SIRT1 activation can also promote glucose transporter type-4
(GLUT4) translocation into cell membranes to facilitate glucose uptake; binding of resveratrol to
estrogen receptors can enhance GLUT4 translocation. Moreover, we propose that both SIRT1 and
estrogen receptor activation by resveratrol can increase endothelial nitric oxide synthase (eNOS) activity
to augment blood flow in skeletal muscle, thereby further enhancing glucose delivery, uptake and
substrate utilisation for energy production and reducing circulating blood glucose and insulin levels.
Akt: protein kinase-B. PGC1α: peroxisome proliferator-activated receptor-γ coactivator-1α.
The vasodilator benefit of resveratrol extends to ameliorating microvascular dysfunction in the
cerebral vessels of adults with T2DM, who have reduced cerebral perfusion, impaired cognitive
function, and are at greater risk of developing dementia [56,57]. Similar to the FMD technique used
in the systemic vasculature, a consistent hyperaemia can be achieved in cerebral vessels such as
the middle cerebral artery by inhaling 5% carbon dioxide mixed with 95% oxygen (Carbogen gas).
The magnitude of increase in blood flow velocity monitored by transcranial Doppler ultrasound
reflects the vessel’s capacity to dilate effectively [58]. We recently demonstrated that the lowest dose of
resveratrol tested (75 mg) afforded the maximum increase in cerebral vasodilator responsiveness
to both hypercapnic and cognitive provocation compared to 150 mg and 300 mg doses [59,60].
Furthermore, we were able to confirm that chronic supplementation for 14 weeks with 150 mg/day of
resveratrol resulted in sustained improvements of cerebrovascular responsiveness in postmenopausal
women [61]. Women following menopause are equally, if not more, vulnerable to chronic diseases such
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as cognitive impairment, T2DM and osteoporosis [62–64]; these conditions are partially attributable to
poor circulatory function. Hence, the sex difference in responsiveness to resveratrol warrants further
investigation, as it may have potential to counteract endothelial dysfunction that is accelerated by
estrogen deficiency at menopause.
A single dose of resveratrol is unlikely to reduce arterial blood pressure, as seen in our study [51]
and others [55]. However with regular supplementation, the functional changes of the vasculature
may translate into favorable outcomes for arterial blood pressure. A meta-analysis of six studies
reported a –5.66 mmHg non-significant reduction in systolic blood pressure; diastolic blood pressure
was however unaffected with resveratrol supplementation. The lack of a clear antihypertensive
benefit with resveratrol is suggested to be dose-dependent; at least 150 mg/day appears necessary in
overweight and obese adults with established metabolic disturbances [4].
To date, no studies have evaluated whether the improvement in vascular function with resveratrol
is accompanied by enhancement of insulin sensitivity in adults with metabolic dysregulation.
Nonetheless, similar vasoactive nutrients such as cocoa flavanols that are well known to have favorable
effects on FMD [65] have been shown to improve insulin sensitivity in hypertensive patients with
impaired glucose tolerance. Compared to flavanol-free white chocolate, 100 g/day of flavanol-rich
dark chocolate for 15 days significantly improved insulin sensitivity, as measured by HOMA-IR,
β-cell function and arterial blood pressure. In fact, the changes in insulin sensitivity and β-cell function
directly correlated with FMD enhancements (r = 0.510) and blood pressure reduction [66]. Recently
more bioactives have been shown to have promising effects.
3. Conclusions
We have summarized the possible mechanisms by which resveratrol may act to improve insulin
sensitivity, with particular emphasis on the role of the microcirculation to improve/delivery of glucose
and fatty acids to skeletal muscles. These are summarized in Figure 1. Whilst the clinical trial
evidence for metabolic health improvements with resveratrol is mixed, partly due to variations
in dose levels used, subject selection, trial duration, present comorbidities and medication use,
the positive effects of resveratrol on vascular health are consistent, emphasizing the potential
importance of skeletal muscle perfusion in the prevention of T2D. The effectiveness of resveratrol
for improving insulin sensitivity, mediated by SIRT1–AMPK, ER and eNOS activation, appears to
be limited to overweight/obese/insulin resistant individuals with impaired endothelial function.
In fact, clinical evidence supports the reversibility of endothelial dysfunction and the normalization
of metabolic homeostasis. Further studies to identify the optimal resveratrol dose for improving,
preventing and managing T2DM are urgently warranted. In view of the potential importance of the
phytoestrogenic effects of resveratrol on glucose metabolism, including the improvement of skeletal
muscle perfusion, sex differences in responsiveness to resveratrol treatment should also be evaluated.
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